TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $894,000 | -65.3% | 100,000 | 0.0% | 0.25% | -39.1% |
| Q1 2022 | $2,577,000 | +66.0% | 100,000 | +100.0% | 0.41% | -27.0% |
| Q4 2021 | $1,552,000 | -68.0% | 50,000 | -75.0% | 0.56% | -54.0% |
| Q3 2021 | $4,850,000 | -11.7% | 200,000 | -9.1% | 1.22% | -34.3% |
| Q1 2021 | $5,493,000 | – | 220,000 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |